Technology Platform

CURADIGM ANNOUNCES 1 MILLION € FUNDING FROM BPI FRANCE’S DEEP TECH PROGRAM TO SUPPORT DEVELOPMENT OF THE NANOPRIMER PLATFORM

CURADIGM ANNOUNCES 1 MILLION € FUNDING FROM BPI FRANCE’S DEEP TECH PROGRAM TO SUPPORT DEVELOPMENT OF THE NANOPRIMER PLATFORM

Curadigm today announced the receipt of 1 Million € in non-dilutive funding from Deep Tech BPI France for the development of their Nanoprimer technology. The Deep Tech program recognizes biotechnology companies with breakthrough innovation and strong commercial potential. The funding award highlights the Nanoprimer’s unique, groundbreaking approach to increasing therapeutic bioavailability and efficacy, which is applicable across multiple drug classes. […]

Continue Reading...

CURADIGM ANNOUNCES PUBLICATION OF RESULTS USING PROPRIETARY NANOPRIMER TO IMPROVE RNA THERAPEUTICS IN COLLABORATION WITH THE LANGER LAB

CURADIGM ANNOUNCES PUBLICATION OF RESULTS USING PROPRIETARY NANOPRIMER TO IMPROVE RNA THERAPEUTICS IN COLLABORATION WITH THE LANGER LAB

The data generated during this fruitful collaboration with Prof. Langer’s lab and published in Nano Letters are very important for Curadigm. it represents an external validation of our concept to address the unmet needs of nucleic acid - based therapeutics. The potential of the Nanoprimer to improve treatment efficacy by avoiding liver clearance is a great opportunity to accelerate the development of RNA-based therapeutics and to bring a real benefit for the patients. […]

Continue Reading...

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy, announced the selection of its Nanoprimer technology by the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization, based on its potential to significantly impact treatments in multiple disease indications, including cancer. […]

Continue Reading...

NANOBIOTIX ANNOUNCES THE LAUNCH OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR HEALTHCARE

NANOBIOTIX ANNOUNCES THE LAUNCH OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR HEALTHCARE

After achieving the milestone of our first European market approval for Nanobiotix’s lead oncology product candidate, NBTXR3, our business continues to build momentum. We are thrilled to announce the launch of our subsidiary, Curadigm—another disruptive technology platform we have built as a result of pioneering nanomedicine for more than 15 years. While Nanobiotix remains focused on continued development of NBTXR3, we are pleased to open new growth pathways for our business and shareholders. […]

Continue Reading...